X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3589) 3589
Publication (489) 489
Newsletter (79) 79
Newspaper Article (38) 38
Book Review (36) 36
Book Chapter (15) 15
Dissertation (14) 14
Magazine Article (14) 14
Conference Proceeding (5) 5
Trade Publication Article (2) 2
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
efavirenz (3216) 3216
humans (2050) 2050
index medicus (1644) 1644
hiv infections - drug therapy (1479) 1479
infectious diseases (1316) 1316
male (1272) 1272
hiv (1258) 1258
female (1240) 1240
adult (1115) 1115
antiretroviral therapy (908) 908
pharmacology & pharmacy (879) 879
immunology (755) 755
middle aged (740) 740
anti-hiv agents - therapeutic use (716) 716
nevirapine (684) 684
antiviral agents (635) 635
human immunodeficiency virus--hiv (554) 554
therapy (541) 541
drug therapy (540) 540
antiretroviral drugs (538) 538
virology (529) 529
hiv infection (521) 521
pharmacokinetics (479) 479
highly active antiretroviral therapy (461) 461
tenofovir (449) 449
microbiology (443) 443
treatment outcome (433) 433
research (425) 425
hiv infections - virology (419) 419
anti-hiv agents - adverse effects (409) 409
aids (406) 406
anti-hiv agents - administration & dosage (401) 401
viral load (397) 397
lamivudine (396) 396
protease inhibitors (379) 379
hiv-1 - drug effects (376) 376
emtricitabine (363) 363
cd4 lymphocyte count (345) 345
analysis (334) 334
health aspects (333) 333
hiv-1 (329) 329
reverse transcriptase inhibitors - therapeutic use (329) 329
benzoxazines - therapeutic use (308) 308
dosage and administration (306) 306
antiretroviral agents (302) 302
drug therapy, combination (289) 289
risk factors (287) 287
aids/hiv (284) 284
antiretroviral therapy, highly active (278) 278
drugs (277) 277
hiv-infected patients (274) 274
infection (274) 274
young adult (269) 269
acquired immune deficiency syndrome--aids (259) 259
virus diseases (258) 258
ritonavir (257) 257
efficacy (256) 256
zidovudine (249) 249
safety (247) 247
adolescent (242) 242
article (242) 242
hiv-1-infected patients (242) 242
human immunodeficiency virus (242) 242
care and treatment (241) 241
hiv infections - complications (237) 237
anti-hiv agents - pharmacokinetics (234) 234
benzoxazines - administration & dosage (232) 232
drug interactions (231) 231
pharmacogenetics (230) 230
adults (225) 225
anti-hiv agents - pharmacology (224) 224
hiv-1 - genetics (222) 222
reverse-transcriptase inhibitors (221) 221
hiv patients (220) 220
benzoxazines - adverse effects (213) 213
medicine (208) 208
adherence (203) 203
drug resistance (202) 202
lopinavir (202) 202
benzoxazines (199) 199
aged (196) 196
mutation (196) 196
patients (196) 196
tuberculosis (196) 196
research article (195) 195
adenine - analogs & derivatives (193) 193
complications and side effects (192) 192
benzoxazines - pharmacokinetics (191) 191
prospective studies (191) 191
reverse transcriptase inhibitors - adverse effects (187) 187
human-immunodeficiency-virus (186) 186
genotype (185) 185
clinical trials (184) 184
active antiretroviral therapy (183) 183
cohort studies (180) 180
toxicity (180) 180
anti-hiv agents (179) 179
pharmacology (175) 175
retrospective studies (175) 175
cyp2b6 (174) 174
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3618) 3618
Spanish (58) 58
French (36) 36
German (17) 17
Portuguese (10) 10
Japanese (4) 4
Polish (3) 3
Chinese (2) 2
Afrikaans (1) 1
Dutch (1) 1
Italian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 2011, Volume 154, Issue 7, pp. 445 - 456
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign,... 
Atazanavir | Ritonavir | Research | Drug therapy | Health aspects | Efavirenz | HIV infection
Journal Article
Rapid communications in mass spectrometry : RCM, ISSN 0951-4198, 4/2018, Volume 32, Issue 8, pp. 657 - 664
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 12/2019, Volume 140, p. 105068
Maternofoetal physiologically-based pharmacokinetic models integrating multi-compartmental maternal and foetal units were developed using Simbiology® to... 
Pregnancy | Fetus | Efavirenz | Thalidomide | PBPK model
Journal Article
09/2013
Background: There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future... 
once-a-day therapy | Lamivudine and Efavirenz | Didanosine | child
Web Resource
Frontiers in Bioscience - Landmark, ISSN 1093-9946, 01/2018, Volume 23, Issue 7, pp. 1292 - 1309
Journal Article
LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2014, Volume 14, Issue 7, pp. 572 - 580
Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether dual... 
INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | SAFETY | ANALOGS | EFAVIRENZ | LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | SPARING REGIMEN | TENOFOVIR/EMTRICITABINE
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 10/2019, Volume 570, p. 118597
Efavirenz (EFZ) and tenofovir disoproxil fumarate (TDF) can be used simultaneously in the treatment of human immunodeficiency virus type1 infection. In this... 
Eutectic mixture | Efavirenz | Dissolution | Tenofovir disoproxil fumarate | Solubility
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 07/2018, Volume 104, Issue 1, pp. 130 - 138
CYP2B6*6 and CYP2B6*18 are the most clinically important variants causing reduced CYP2B6 protein expression and activity. However, these variants do not... 
SNP | polymorphism | metabolism | CYP | bupropion | pharmacogenetics | efavirenz
Journal Article
Journal Article
Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2016, Volume 6, Issue 5, pp. 413 - 425
Mounting evidence demonstrates that CYP2B6 plays a much larger role in human drug metabolism than was previously believed. The discovery of multiple important... 
Cyclophosphamide | CYP2B6 | CAR | PXR | Drug-drug interaction | Efavirenz | Polymorphism | HUMAN CYTOCHROME P4502B6 | PATIENT-CONTROLLED ANALGESIA | EFAVIRENZ-CONTAINING REGIMENS | HUMAN LIVER-MICROSOMES | PREGNANE-X-RECEPTOR | DISRUPTOR PESTICIDE-METHOXYCHLOR | CONSTITUTIVE ANDROSTANE RECEPTOR | PHARMACOLOGY & PHARMACY | IN-VITRO BIOTRANSFORMATION | HUMAN CYP2B6 GENE | RESPONSIVE ENHANCER MODULE | IFA, Ifosfamide | DEX, dexamethasone | HNF, hepatocyte nuclear factor | Review | CITCO, (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) | NVP, nevirapine | 2, nuclear receptor binding site 1 | GRE, glucocorticoid responsive element | MAOI, monoamine oxidase inhibitor | PXR, pregnane X receptor | CYP, cytochrome P450 | enhancer-binding protein | UGT, UDP-glucuronosyl transferase | PCN, pregnenolone 16 alpha-carbonitrile | PBREM, phenobarbital-responsive enhancer module | Drug–drug interaction | EBP, CCAAT | CAR, constitutive androstane receptor | COUP-TF, chicken ovalbumin upstream promoter-transcription factor | ERE, estrogen responsive element | HAART, highly active antiretroviral therapy | NR1 | PB, phenobarbital | NNRTI, non-nucleotide reverse-transcriptase inhibitor | CPA, cyclophosphamide | SNP, single nucleotide polymorphism | TCPOBOP, 1,4-bis[3,5-dichloropyridyloxy]benzene | CHOP, cyclophosphamide–doxorubicin–vincristine–prednisone | 4-OH-CPA, 4-hydroxycyclophosphamide | DDI, drug–drug interaction | EFV, efavirenz | GR, glucocorticoid receptor | E2, estradiol | RIF, rifampin
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 07/2004, Volume 319, Issue 4, pp. 1322 - 1326
Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver. We analyzed the genotypes of CYP2B6 and their contribution to plasma EFV... 
HIV-1 | Cytochrome P450 | Genetic polymorphism | Plasma concentration | Efavirenz
Journal Article
Journal Article